Literature DB >> 15595804

Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates.

Kyeongsoon Park1, Kwangmeyung Kim, Ick Chan Kwon, Sang Kyoon Kim, Seulki Lee, Dong Yun Lee, Youngro Byun.   

Abstract

Various deoxycholic acid (DOCA) bearing heparin (HD) amphiphilic conjugates with different degrees of substitution (DS) with DOCA were synthesized using heparin as a hydrophilic segment and DOCA as a hydrophobic segment. Structural characteristics of these HD conjugates were investigated using 1H NMR, dynamic light scattering, zeta potential, transmission electron microscopy (TEM), and fluorescence spectroscopy. HD conjugates provided monodispersed self-aggregates in water, with mean diameters decreasing with increasing DOCA DS in the range of 120-200 nm. HD aggregates were covered with negatively charged heparin shells, exhibiting xi potentials near -56 mV. The critical aggregation concentration (cac) of the HD (0.02-0.003 mg/mL) depended upon DOCA DS. TEM images demonstrated that the shape of the self-aggregates was spherical. Partition equilibrium constants, Kv, for pyrene in the self-aggregates in water indicated that increasing DS enhanced the hydrophobicity of the self-aggregate inner core. The mean aggregation number of DOCA per hydrophobic microdomain, estimated by the fluorescence quenching methods using cetylpyridinium chloride, indicated that five to nine of HD chains comprised a hydrophobic domain in the conjugates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15595804     DOI: 10.1021/la048646i

Source DB:  PubMed          Journal:  Langmuir        ISSN: 0743-7463            Impact factor:   3.882


  20 in total

Review 1.  Nanotechnology for computed tomography: a real potential recently disclosed.

Authors:  Nicolas Anton; Thierry F Vandamme
Journal:  Pharm Res       Date:  2013-07-30       Impact factor: 4.200

2.  Advances of cancer therapy by nanotechnology.

Authors:  Xu Wang; Yiqing Wang; Zhuo Georgia Chen; Dong M Shin
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

Review 3.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

4.  The structure of monomeric components of self-assembling CXCR4 antagonists determines the architecture of resulting nanostructures.

Authors:  Youngshim Lee; Yuhong Chen; Nadya I Tarasova; Vadim Gaponenko
Journal:  Nanotechnology       Date:  2011-11-23       Impact factor: 3.874

5.  Antiangiogenic effect of bile acid acylated heparin derivative.

Authors:  Kyeongsoon Park; Yoo-Shin Kim; Gee Young Lee; Ju-Ock Nam; Seok Ki Lee; Rang-Woon Park; Sang Yoon Kim; In-San Kim; Youngro Byun
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.200

Review 6.  Application of polysaccharides for surface modification of nanomedicines.

Authors:  Kyung-Oh Doh; Yoon Yeo
Journal:  Ther Deliv       Date:  2012-12

7.  Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth.

Authors:  Kyeongsoon Park; Yoo-Shin Kim; Gee Young Lee; Rang-Woon Park; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

8.  Engineered andrographolide nanoparticles mitigate paracetamol hepatotoxicity in mice.

Authors:  Partha Roy; Suvadra Das; Runa Ghosh Auddy; Achintya Saha; Arup Mukherjee
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

9.  Modest anti-cancer activity of a bile acid acylated heparin derivative in a PC14PE6 induced orthotopic lung cancer model.

Authors:  Zheng Yun Cui; Min Jae Park; Jeeyun Lee; Jin Seok Ahn; Myung Ju Ahn; Soo Won Seo; Jin Woo Park; Youngro Byun; Keunchil Park
Journal:  Cancer Res Treat       Date:  2009-06-30       Impact factor: 4.679

10.  Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma.

Authors:  Kyeongsoon Park; Gee Young Lee; Rang-Woon Park; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2007-07-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.